146 related articles for article (PubMed ID: 37945404)
1. Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries.
Milloy N; Kirker M; Unsworth M; Montgomery R; Kluth C; Kearney M; Chang J
Clin Genitourin Cancer; 2024 Feb; 22(1):e136-e147.e1. PubMed ID: 37945404
[TBL] [Abstract][Full Text] [Related]
2. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
4. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
[TBL] [Abstract][Full Text] [Related]
5. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
6. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
7. Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
Maráz A; Nagy B; Macher T; Jeskó J; Tischler E; Csongvai C; Kearney M
Adv Ther; 2023 Dec; 40(12):5475-5488. PubMed ID: 37831384
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
Gupta S; Costantino H; Ike C; Gupta S; Bhanegaonkar A; Su C; Thakkar S; Mackie DS; Devgan G; Katzenstein HM; Liu FX
Oncologist; 2024 Mar; 29(3):244-253. PubMed ID: 37846191
[TBL] [Abstract][Full Text] [Related]
9. Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.
Grivas P; Huber C; Pawar V; Roach M; May SG; Desai I; Chang J; Bharmal M
Clin Genitourin Cancer; 2022 Apr; 20(2):114-122. PubMed ID: 34903481
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Leith A; Kim J; Ribbands A; Clayton E; Yang L; Ghate SR
Adv Ther; 2022 May; 39(5):2236-2255. PubMed ID: 35316501
[TBL] [Abstract][Full Text] [Related]
11. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Bailey H; Lee A; Eccles L; Yuan Y; Burlison H; Forshaw C; Varol N
BMC Cancer; 2023 Jun; 23(1):603. PubMed ID: 37386452
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
[TBL] [Abstract][Full Text] [Related]
15. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
16. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
Gupta S; Andreev-Drakhlin A; Fajardo O; Fassò M; Garcia JA; Wee C; Schröder C
J Natl Cancer Inst; 2024 Apr; 116(4):547-554. PubMed ID: 38036464
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
Fleming S; Gifkins D; Resnick HE; Shalaby W; Rosenberg P; Gaj C; Maio V; Crawford A; Lu-Yao G; Gao J; Siefker-Radtke A
Clin Genitourin Cancer; 2024 Jun; 22(3):102054. PubMed ID: 38457853
[TBL] [Abstract][Full Text] [Related]
20. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Houédé N; Locker G; Lucas C; Parra HS; Basso U; Spaeth D; Tambaro R; Basterretxea L; Morelli F; Theodore C; Lusuardi L; Lainez N; Guillot A; Tonini G; Bielle J; Del Muro XG
BMC Cancer; 2016 Sep; 16(1):752. PubMed ID: 27664126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
